← Back to Search

Monoclonal Antibodies

SHR-A1811 for Solid Tumors

Phase 1
Recruiting
Research Sponsored by Jiangsu HengRui Medicine Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

Study Summary

This trial is testing a new drug to see if it is safe and effective against HER2-expressing solid tumors.

Eligible Conditions
  • Advanced Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence and severity of adverse events (AEs)
Secondary outcome measures
Immunogenicity of SHR-A1811
PK parameter: AUC0-t of SHR-A1811
PK parameter: Cmax of SHR-A1811
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Part 2 Indication expansionExperimental Treatment1 Intervention
Group II: Part 1 Dose escalationExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Jiangsu HengRui Medicine Co., Ltd.Lead Sponsor
625 Previous Clinical Trials
94,571 Total Patients Enrolled
Atridia Pty Ltd.Industry Sponsor
25 Previous Clinical Trials
772 Total Patients Enrolled

Media Library

SHR-A1811 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04446260 — Phase 1
Solid Tumors Research Study Groups: Part 1 Dose escalation, Part 2 Indication expansion
Solid Tumors Clinical Trial 2023: SHR-A1811 Highlights & Side Effects. Trial Name: NCT04446260 — Phase 1
SHR-A1811 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04446260 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research initiative currently seeking participants?

"As per clinicaltrials.gov, the search for participants in this medical trial is still underway. It was first published on September 3rd 2020 with its most recent update occurring on December 22nd 2021."

Answered by AI

How widely distributed is the trial being conducted in this metropolitan area?

"Patients can participate in this study at the Mary Crowley Cancer Research centre located in Dallas, Montefiore-Einstein Center for Cancer Care situated within Bronx, and Gabrail Cancer Research Center based out of Canton; there are 2 other sites as well."

Answered by AI

What is the aggregate sum of participants in this trial?

"This research necessitates the recruitment of 226 qualified individuals to participate in this medical trial. Candidates can join from Mary Crowley Cancer Research (Texas) or Montefiore-Einstein Center for Cancer Care (New york)."

Answered by AI

What dangers have been associated with utilization of SHR-A1811?

"Our assessment of SHR-A1811's safety was marked at 1, as this is a preliminary trial with limited evidence for both efficacy and safety."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors
2020. "A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04446260.
~49 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top